These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457 [TBL] [Abstract][Full Text] [Related]
3. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment]. Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251 [TBL] [Abstract][Full Text] [Related]
4. The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders. MacKenzie EM; Odontiadis J; Le Mellédo JM; Prior TI; Baker GB Cell Mol Neurobiol; 2007 Aug; 27(5):541-74. PubMed ID: 17235696 [TBL] [Abstract][Full Text] [Related]
5. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. O'Connor WT; O'Shea SD Pharmacol Ther; 2015 Jun; 150():47-80. PubMed ID: 25585121 [TBL] [Abstract][Full Text] [Related]
6. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Guillin O; Demily C; Thibaut F Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in the neurobiology of schizophrenia. Miyamoto S; LaMantia AS; Duncan GE; Sullivan P; Gilmore JH; Lieberman JA Mol Interv; 2003 Feb; 3(1):27-39. PubMed ID: 14993436 [TBL] [Abstract][Full Text] [Related]
8. Alterations of serotonin transmission in schizophrenia. Abi-Dargham A Int Rev Neurobiol; 2007; 78():133-64. PubMed ID: 17349860 [TBL] [Abstract][Full Text] [Related]
9. Integrating the neurobiology of schizophrenia. Preface. Abi-Dargham A; Guillin O Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855 [No Abstract] [Full Text] [Related]
10. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Marx CE; Stevens RD; Shampine LJ; Uzunova V; Trost WT; Butterfield MI; Massing MW; Hamer RM; Morrow AL; Lieberman JA Neuropsychopharmacology; 2006 Jun; 31(6):1249-63. PubMed ID: 16319920 [TBL] [Abstract][Full Text] [Related]
11. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia]. Maćkowiak M; Czyrak A; Wedzony K Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260 [TBL] [Abstract][Full Text] [Related]
12. [Pathophysiology of schizophrenia and its impact on pharmacotherapy]. Widschwendter CG; Fleischhacker WW Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242 [TBL] [Abstract][Full Text] [Related]
13. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Berman JA; Talmage DA; Role LW Int Rev Neurobiol; 2007; 78():193-223. PubMed ID: 17349862 [TBL] [Abstract][Full Text] [Related]
14. The role of the central histaminergic system on schizophrenia. Ito C Drug News Perspect; 2004; 17(6):383-7. PubMed ID: 15334189 [TBL] [Abstract][Full Text] [Related]
15. A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA; Saklad SR Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797 [TBL] [Abstract][Full Text] [Related]
16. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors. Harrison PJ Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896 [No Abstract] [Full Text] [Related]
17. The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines. Boczek T; Mackiewicz J; Sobolczyk M; Wawrzyniak J; Lisek M; Ferenc B; Guo F; Zylinska L Cells; 2021 May; 10(5):. PubMed ID: 34067760 [TBL] [Abstract][Full Text] [Related]
19. Schizophrenia as a disorder of neuroplasticity. McCullumsmith RE; Clinton SM; Meador-Woodruff JH Int Rev Neurobiol; 2004; 59():19-45. PubMed ID: 15006483 [TBL] [Abstract][Full Text] [Related]
20. Biological perspectives: the role of glutamate in schizophrenia and its treatment. Steele D; Moore RL; Swan NA; Grant JS; Keltner NL Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]